Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
2022-10-18 20:50
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
2022-08-24 20:50
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology
2022-08-18 20:50
CARsgen Appoints Dr. Hua Jiang as Executive Director
2022-08-02 20:50
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
2022-06-06 20:50
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
2022-05-10 20:50
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
2022-04-07 23:42
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
2022-03-23 20:50
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies
2022-03-23 20:50
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
2022-03-03 21:50
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
2022-01-17 21:50
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
2022-01-10 21:50
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting
2021-12-13 20:00
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041
2021-11-22 20:00
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA
2021-11-15 22:10
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
2021-09-20 08:24
CARsgen Therapeutics officially listing on HKEX
2021-06-19 02:57
1
2